Cargando…
Moderately elevated lipoprotein (a) levels are associated with an earlier need for percutaneous coronary intervention in recurrent cardiovascular disease
A significant number of cardiovascular disease (CVD) patients, with the target lipid levels, as set by the guidelines, achieved, continue to remain at risk. In this setting, lipoprotein (Lp) a role in CVD prognosis is regaining interest. Although Lp(a) is related to the arteriosclerotic process, the...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9199069/ https://www.ncbi.nlm.nih.gov/pubmed/35720629 http://dx.doi.org/10.3892/etm.2022.11371 |
_version_ | 1784727776354369536 |
---|---|
author | Hoursalas, Athanasios Tsarouhas, Konstantinos Tsitsimpikou, Christina Kolovou, Genovefa Vardavas, Alexander Hoursalas, Ioannis Spandidos, Demetrios A. Milionis, Haralampos Elisaf, Moses Tsiara, Stavroula |
author_facet | Hoursalas, Athanasios Tsarouhas, Konstantinos Tsitsimpikou, Christina Kolovou, Genovefa Vardavas, Alexander Hoursalas, Ioannis Spandidos, Demetrios A. Milionis, Haralampos Elisaf, Moses Tsiara, Stavroula |
author_sort | Hoursalas, Athanasios |
collection | PubMed |
description | A significant number of cardiovascular disease (CVD) patients, with the target lipid levels, as set by the guidelines, achieved, continue to remain at risk. In this setting, lipoprotein (Lp) a role in CVD prognosis is regaining interest. Although Lp(a) is related to the arteriosclerotic process, there is not currently an adequate amount of data for the inclusion of Lp(a) levels as a primary therapeutic target in the treatment of coronary artery disease (CAD) patients. In this framework, the current retrospective study aims to investigate the association of Lp(a) levels with the adverse cardiovascular (CV) events presented in a 10 year follow-up of CVD patients with dyslipidemia and its association with the major CV risk factors. A statistically significant reduction in Lp(a) levels was observed during the follow-up period (72.8±45.6 vs. 68.3±41.8 mg/dl; McNemar test; P<0.001). The vast majority of patients who suffered a new acute myocardial infarction during the follow up period had Lp(a) levels >30 mg/dl (24/28 patients, mean ± standard deviation Lp(a), 83.1±36.6 mg/dl, P=0.001). Kaplan-Meier survival analysis did not find statistically significant differences in a percutaneous coronary intervention (PCI) time occurrence during the follow-up period between patients with low (≤30 mg/dl) and high (>30 mg/dl) Lp(a) levels (log-rank P=0.305). On the other hand, when a second and third PCI conducted during the monitoring period were included in the Kaplan Meier analysis as events, the mean time for a PCI was significantly shorter (7.2%; P=0.01) for patients with Lp(a) levels >30 mg/dl. In conclusion, the current study reported that patients with high Lp(a) values are more prone to the occurrence of new myocardial infarction, while the Lp(a) cut-off value of 30 mg/dl was linked in CVD patients to an earlier need for PCI, especially in the most vulnerable group of patients with more than one (recurrent) revascularizations. |
format | Online Article Text |
id | pubmed-9199069 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | D.A. Spandidos |
record_format | MEDLINE/PubMed |
spelling | pubmed-91990692022-06-17 Moderately elevated lipoprotein (a) levels are associated with an earlier need for percutaneous coronary intervention in recurrent cardiovascular disease Hoursalas, Athanasios Tsarouhas, Konstantinos Tsitsimpikou, Christina Kolovou, Genovefa Vardavas, Alexander Hoursalas, Ioannis Spandidos, Demetrios A. Milionis, Haralampos Elisaf, Moses Tsiara, Stavroula Exp Ther Med Articles A significant number of cardiovascular disease (CVD) patients, with the target lipid levels, as set by the guidelines, achieved, continue to remain at risk. In this setting, lipoprotein (Lp) a role in CVD prognosis is regaining interest. Although Lp(a) is related to the arteriosclerotic process, there is not currently an adequate amount of data for the inclusion of Lp(a) levels as a primary therapeutic target in the treatment of coronary artery disease (CAD) patients. In this framework, the current retrospective study aims to investigate the association of Lp(a) levels with the adverse cardiovascular (CV) events presented in a 10 year follow-up of CVD patients with dyslipidemia and its association with the major CV risk factors. A statistically significant reduction in Lp(a) levels was observed during the follow-up period (72.8±45.6 vs. 68.3±41.8 mg/dl; McNemar test; P<0.001). The vast majority of patients who suffered a new acute myocardial infarction during the follow up period had Lp(a) levels >30 mg/dl (24/28 patients, mean ± standard deviation Lp(a), 83.1±36.6 mg/dl, P=0.001). Kaplan-Meier survival analysis did not find statistically significant differences in a percutaneous coronary intervention (PCI) time occurrence during the follow-up period between patients with low (≤30 mg/dl) and high (>30 mg/dl) Lp(a) levels (log-rank P=0.305). On the other hand, when a second and third PCI conducted during the monitoring period were included in the Kaplan Meier analysis as events, the mean time for a PCI was significantly shorter (7.2%; P=0.01) for patients with Lp(a) levels >30 mg/dl. In conclusion, the current study reported that patients with high Lp(a) values are more prone to the occurrence of new myocardial infarction, while the Lp(a) cut-off value of 30 mg/dl was linked in CVD patients to an earlier need for PCI, especially in the most vulnerable group of patients with more than one (recurrent) revascularizations. D.A. Spandidos 2022-05-13 /pmc/articles/PMC9199069/ /pubmed/35720629 http://dx.doi.org/10.3892/etm.2022.11371 Text en Copyright: © Hoursalas et al. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. |
spellingShingle | Articles Hoursalas, Athanasios Tsarouhas, Konstantinos Tsitsimpikou, Christina Kolovou, Genovefa Vardavas, Alexander Hoursalas, Ioannis Spandidos, Demetrios A. Milionis, Haralampos Elisaf, Moses Tsiara, Stavroula Moderately elevated lipoprotein (a) levels are associated with an earlier need for percutaneous coronary intervention in recurrent cardiovascular disease |
title | Moderately elevated lipoprotein (a) levels are associated with an earlier need for percutaneous coronary intervention in recurrent cardiovascular disease |
title_full | Moderately elevated lipoprotein (a) levels are associated with an earlier need for percutaneous coronary intervention in recurrent cardiovascular disease |
title_fullStr | Moderately elevated lipoprotein (a) levels are associated with an earlier need for percutaneous coronary intervention in recurrent cardiovascular disease |
title_full_unstemmed | Moderately elevated lipoprotein (a) levels are associated with an earlier need for percutaneous coronary intervention in recurrent cardiovascular disease |
title_short | Moderately elevated lipoprotein (a) levels are associated with an earlier need for percutaneous coronary intervention in recurrent cardiovascular disease |
title_sort | moderately elevated lipoprotein (a) levels are associated with an earlier need for percutaneous coronary intervention in recurrent cardiovascular disease |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9199069/ https://www.ncbi.nlm.nih.gov/pubmed/35720629 http://dx.doi.org/10.3892/etm.2022.11371 |
work_keys_str_mv | AT hoursalasathanasios moderatelyelevatedlipoproteinalevelsareassociatedwithanearlierneedforpercutaneouscoronaryinterventioninrecurrentcardiovasculardisease AT tsarouhaskonstantinos moderatelyelevatedlipoproteinalevelsareassociatedwithanearlierneedforpercutaneouscoronaryinterventioninrecurrentcardiovasculardisease AT tsitsimpikouchristina moderatelyelevatedlipoproteinalevelsareassociatedwithanearlierneedforpercutaneouscoronaryinterventioninrecurrentcardiovasculardisease AT kolovougenovefa moderatelyelevatedlipoproteinalevelsareassociatedwithanearlierneedforpercutaneouscoronaryinterventioninrecurrentcardiovasculardisease AT vardavasalexander moderatelyelevatedlipoproteinalevelsareassociatedwithanearlierneedforpercutaneouscoronaryinterventioninrecurrentcardiovasculardisease AT hoursalasioannis moderatelyelevatedlipoproteinalevelsareassociatedwithanearlierneedforpercutaneouscoronaryinterventioninrecurrentcardiovasculardisease AT spandidosdemetriosa moderatelyelevatedlipoproteinalevelsareassociatedwithanearlierneedforpercutaneouscoronaryinterventioninrecurrentcardiovasculardisease AT milionisharalampos moderatelyelevatedlipoproteinalevelsareassociatedwithanearlierneedforpercutaneouscoronaryinterventioninrecurrentcardiovasculardisease AT elisafmoses moderatelyelevatedlipoproteinalevelsareassociatedwithanearlierneedforpercutaneouscoronaryinterventioninrecurrentcardiovasculardisease AT tsiarastavroula moderatelyelevatedlipoproteinalevelsareassociatedwithanearlierneedforpercutaneouscoronaryinterventioninrecurrentcardiovasculardisease |